• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

嘧啶类 SARS-CoV 3CL 蛋白酶抑制剂的合成、对接研究及评价。

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

机构信息

Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.

出版信息

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3569-72. doi: 10.1016/j.bmcl.2010.04.118. Epub 2010 May 20.

DOI:10.1016/j.bmcl.2010.04.118
PMID:20494577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7126861/
Abstract

A series of 2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Two candidates had encouraging results for the development of new anti-SARS compounds.

摘要

一系列 2-(苄硫基)-6-氧代-4-苯基-1,6-二氢嘧啶作为 SARS-CoV 3CL 蛋白酶抑制剂被开发出来，并通过体外蛋白酶抑制试验评估了它们的活性。有两个候选化合物为开发新型抗 SARS 化合物提供了有希望的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/e970eb5ab654/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/425dacfea359/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/504889ece515/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/c85b640cb1c8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/e970eb5ab654/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/425dacfea359/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/504889ece515/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/c85b640cb1c8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02b9/7126861/e970eb5ab654/gr2.jpg

相似文献

1
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.嘧啶类 SARS-CoV 3CL 蛋白酶抑制剂的合成、对接研究及评价。
Bioorg Med Chem Lett. 2010 Jun 15;20(12):3569-72. doi: 10.1016/j.bmcl.2010.04.118. Epub 2010 May 20.
2
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.强效SARS-CoV 3CL（蛋白酶）抑制剂的设计、合成及生物学评价的新进展
Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7. doi: 10.1016/j.bmcl.2009.03.118. Epub 2009 Mar 28.
3
Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.一系列丝氨酸衍生物作为严重急性呼吸综合征冠状病毒3CL蛋白酶小分子抑制剂的设计与合成
Bioorg Med Chem. 2016 Mar 15;24(6):1241-54. doi: 10.1016/j.bmc.2016.01.052. Epub 2016 Jan 29.
4
Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.异吲哚酮衍生物作为有效的严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的合成与评价
Bioorg Med Chem Lett. 2005 Jun 15;15(12):3058-62. doi: 10.1016/j.bmcl.2005.04.027.
5
Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.作为严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的辛那色林类似物的设计与合成
Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1400-5. doi: 10.1248/cpb.56.1400.
6
Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.三氟甲基酮作为严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的设计、合成与评估
Bioorg Med Chem. 2008 Apr 15;16(8):4652-60. doi: 10.1016/j.bmc.2008.02.040. Epub 2008 Feb 15.
7
Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.基于结构的高效 SARS-CoV 3CL 蛋白酶抑制剂的设计与合成
Chembiochem. 2007 Sep 24;8(14):1654-7. doi: 10.1002/cbic.200700254.
8
Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.新型 P3 骨架的强效二肽型 SARS-CoV 3CL 蛋白酶抑制剂的研发：设计、合成、生物评价和对接研究。
Eur J Med Chem. 2013 Oct;68:372-84. doi: 10.1016/j.ejmech.2013.07.037. Epub 2013 Aug 9.
9
Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.辛那色林是严重急性呼吸综合征冠状病毒3C样蛋白酶的抑制剂，在体外能强烈降低病毒复制。
J Virol. 2005 Jun;79(11):7095-103. doi: 10.1128/JVI.79.11.7095-7103.2005.
10
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.针对严重急性呼吸综合征3CL蛋白酶的强效酰苯胺类抑制剂的发现。
J Med Chem. 2005 Jun 30;48(13):4469-73. doi: 10.1021/jm050184y.

引用本文的文献

1
Advancements in the development of antivirals against SARS-Coronavirus.抗SARS冠状病毒抗病毒药物的研发进展。
Front Cell Infect Microbiol. 2025 Jan 23;15:1520811. doi: 10.3389/fcimb.2025.1520811. eCollection 2025.
2
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用：全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
3
DFT investigations and molecular docking as potent inhibitors of SARS-CoV-2 main protease of 4-phenylpyrimidine.

本文引用的文献

1
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.强效SARS-CoV 3CL（蛋白酶）抑制剂的设计、合成及生物学评价的新进展
Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7. doi: 10.1016/j.bmcl.2009.03.118. Epub 2009 Mar 28.
2
Individual and common inhibitors of coronavirus and picornavirus main proteases.冠状病毒和小核糖核酸病毒主要蛋白酶的个体及通用抑制剂。
FEBS Lett. 2009 Feb 4;583(3):549-55. doi: 10.1016/j.febslet.2008.12.059. Epub 2009 Jan 21.
3
Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
密度泛函理论研究及分子对接：4-苯基嘧啶作为严重急性呼吸综合征冠状病毒2主蛋白酶的有效抑制剂
J Mol Struct. 2023 Apr 5;1277:134895. doi: 10.1016/j.molstruc.2022.134895. Epub 2022 Dec 30.
4
A new class of half-sandwich ruthenium complexes containing Biginelli hybrids: anticancer and anti-SARS-CoV-2 activities.一类新型半夹心型钌配合物，包含比格利宁杂环：抗癌和抗 SARS-CoV-2 活性。
Chem Biol Interact. 2022 Aug 25;363:110025. doi: 10.1016/j.cbi.2022.110025. Epub 2022 Jun 22.
5
Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review.使用结构多样的抑制剂靶向严重急性呼吸综合征冠状病毒（SARS-CoV-1）：综述
RSC Adv. 2020 Jul 29;10(47):28287-28299. doi: 10.1039/d0ra04395h. eCollection 2020 Jul 27.
6
Quantitative analysis of hydrogen and chalcogen bonds in two pyrimidine-5-carbonitrile derivatives, potential DHFR inhibitors: an integrated crystallographic and theoretical study.两种嘧啶-5-腈衍生物（潜在的二氢叶酸还原酶抑制剂）中氢和硫族元素键的定量分析：一项晶体学与理论相结合的研究
RSC Adv. 2020 Oct 6;10(60):36806-36817. doi: 10.1039/d0ra07215j. eCollection 2020 Oct 1.
7
Synthesis, crystal structure and antibacterial studies of dihydropyrimidines and their regioselectively oxidized products.二氢嘧啶及其区域选择性氧化产物的合成、晶体结构与抗菌研究
RSC Adv. 2021 Feb 3;11(11):6312-6329. doi: 10.1039/d0ra10255e. eCollection 2021 Feb 2.
8
Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.针对肽模拟物和小分子 SARS-CoV 3CLpro 抑制剂的合成和计算研究。
Bioorg Med Chem. 2021 Sep 15;46:116301. doi: 10.1016/j.bmc.2021.116301. Epub 2021 Jul 3.
9
A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics.基于蛋白质动力学分析指导的基于活性的化合物库筛选构建高亲和力SARS-CoV-2 Mpro抑制剂蓝图
ACS Pharmacol Transl Sci. 2021 Mar 16;4(3):1079-1095. doi: 10.1021/acsptsci.0c00215. eCollection 2021 Jun 11.
10
An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease.一种用于鉴定新型冠状病毒3CL蛋白酶抑制剂的综合计算与实验方法
Front Mol Biosci. 2021 May 17;8:661424. doi: 10.3389/fmolb.2021.661424. eCollection 2021.
作为严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的辛那色林类似物的设计与合成
Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1400-5. doi: 10.1248/cpb.56.1400.
4
Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro).针对冠状病毒主要蛋白酶3CL(pro)的广谱卤代甲基酮抑制剂的研发
Chem Biol Drug Des. 2008 Jul;72(1):34-49. doi: 10.1111/j.1747-0285.2008.00679.x.
5
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.基于结构的肽模拟物 SARS-CoV 3CLpro 抑制剂的设计、合成及生物学评价
Bioorg Med Chem Lett. 2007 Nov 1;17(21):5876-80. doi: 10.1016/j.bmcl.2007.08.031. Epub 2007 Aug 19.
6
Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.基于结构的高效 SARS-CoV 3CL 蛋白酶抑制剂的设计与合成
Chembiochem. 2007 Sep 24;8(14):1654-7. doi: 10.1002/cbic.200700254.
7
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.稳定的苯并三唑酯作为严重急性呼吸综合征3CL蛋白酶的基于机制的失活剂。
Chem Biol. 2006 Mar;13(3):261-8. doi: 10.1016/j.chembiol.2005.12.008.
8
A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods.通过筛选和对接方法相结合发现的严重急性呼吸综合征冠状病毒主要蛋白酶非肽类活性位点导向抑制剂的新线索。
J Med Chem. 2005 Nov 3;48(22):6832-42. doi: 10.1021/jm0501782.
9
Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.肽模拟物严重急性呼吸综合征类胰凝乳蛋白酶样蛋白酶抑制剂的设计与合成
J Med Chem. 2005 Nov 3;48(22):6767-71. doi: 10.1021/jm050548m.
10
Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.拟肽α,β-不饱和酯对严重急性呼吸综合征3CL蛋白酶的抑制作用
Bioorg Med Chem. 2005 Sep 1;13(17):5240-52. doi: 10.1016/j.bmc.2005.05.065.